Pharmaceutical News

RSS

LEITAT, JPT and IUCT partner to develop enhanced anticancer therapy

JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG, IUCT and LEITAT announced today their collaboration on the joint development of an enhanced anticancer therapy based on the biofocused targeting of nucleoside analogs linked to small cyclic peptidomimetics.

18 Jan 2012

Counterfeit, substandard drugs threaten progress in controlling malaria in Africa, researchers report

"Hopes of controlling malaria in Africa could be wrecked by criminals who are circulating counterfeit and substandard drugs, threatening millions of lives, scientists" said in a study published in the Malaria Journal last month, the Guardian reports.

18 Jan 2012

Research reports on effectiveness of Scriptaid in breast cancer cell lines

Although endocrine therapy for breast cancer has shown excellent results in controlling the disease, responsiveness to the therapy depends on whether or not there is expression of estrogen receptors in breast cancer cells. Research from the Sbarro Institute for Cancer Research and Molecular Medicine, a nonprofit cancer, cardiovascular and diabetes research center located in Philadelphia, PA, reports on the effectiveness of a new molecule, Scriptaid, that restores receptivity to endocrine therapy in breast cancer cell lines that had tested negative for the expression of estrogen receptors.

18 Jan 2012

Study compares adoptive T-cell therapy with drug-based cancer treatment

In the treatment of large tumors, how effective is adoptive T cell therapy in comparison to drug-based cancer treatment? To answer this question, Dr. Kathleen Anders and Professor Thomas Blankenstein of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch and researchers of the Beckman Research Institute of the City of Hope Cancer Center in Duarte, California, USA designed and carried out a study comparing the two methods. Based on a mouse cancer model, the researchers elucidated the mechanisms of the two different treatments.

18 Jan 2012

Researchers develop simple process for synthesis of artemisinin

The most effective anti-malaria drug can now be produced inexpensively and in large quantities. This means that it will be possible to provide medication for the 225 million malaria patients in developing countries at an affordable price. Researchers at the Max Planck Institute of Colloids and Interfaces in Potsdam and the Freie Universit-t Berlin have developed a very simple process for the synthesis of artemisinin, the active ingredient that pharmaceutical companies could only obtain from plants up to now.

18 Jan 2012

Voraxaze receives FDA approval for treatment of toxic methotrexate levels

The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.

18 Jan 2012

Vitamin D supplements can fight against age-related macular degeneration

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have found that vitamin D reduces the effects of ageing in mouse eyes and improves the vision of older mice significantly. The researchers hope that this might mean that vitamin D supplements could provide a simple and effective way to combat age-related eye diseases, such as macular degeneration (AMD), in people.

17 Jan 2012

Almac, MGB Biopharma partner to manufacture MGB-BP3 gram positive antibacterial compound

MGB Biopharma and Almac's Sciences Business Unit have entered into a collaboration where Almac will manufacture the production of their lead gram positive antibacterial compound MGB-BP3.

17 Jan 2012

Actavis, Scil Proteins sign Reteplase supply agreement

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply agreement with Actavis, one of the world's leading generic pharmaceutical companies, for the future manufacturing of Reteplase.

17 Jan 2012

Neutracorp finalizes new proprietary weight-loss formula

Neutracorp announced today that it has finalized its new proprietary weight-loss formula—including an all-natural Bio-Energy Boost that could help make losing weight easier and faster than ever before.

17 Jan 2012

UBC study: 1 in 10 Canadians cannot afford prescription drugs

One in 10 Canadians have problems affording medications they have been prescribed, and one in four people without drug insurance cannot afford to have their prescriptions filled, according to a study in CMAJ.

17 Jan 2012

UI chemists debunk misconception about amphotericin

With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug.

17 Jan 2012

Animal study confirms dramatic effects of natural formula against prostate cancer

New animal study confirms the dramatic effects of a natural formula against aggressive prostate cancer tumors. Researchers at the Methodist Research Institute at Indiana University conducted the study on mice, using a human prostate cancer xenograft model.

17 Jan 2012

MD Anderson Orlando receives donation to fight against pancreatic cancer

MD Anderson Cancer Center Orlando has received a generous donation to help in the fight against pancreatic cancer. A $75,000 grant, funded by the Shirley E. Noland Foundation, will support the Pancreatic Cancer Translational Research Project at MD Anderson - Orlando.

17 Jan 2012

Multiple medicines use very common: New snapshot of over-50s' medicine habits

A study by NPS in collaboration with the University of Melbourne —published today in the Medical Journal of Australia — has provided new insights into how people use medicines on a daily basis and highlights that the use of multiple medicines in older Australians is common and more complex than previously thought.

15 Jan 2012

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

Genentech, a member of the Roche Group, today announced it will make its first milestone payment to ForSight VISION4, Inc. as part of an exclusive license agreement to develop the company's investigational drug delivery device, designed to provide sustained delivery of Lucentis (ranibizumab).

13 Jan 2012

Survey reveals high interest in Xalkori among medical oncologists

According to survey results gathered from 80 Medical Oncologists in the United States there is an extreme interest in Xalkori, with 75% of respondents stating a high interest in prescribing the product, virtually no physicians stating they have low interest in prescribing the therapy.

13 Jan 2012

CVS agrees to pay $5M to settle Medicare drug false advertising claims

After more than two years of investigation, CVS Caremark agreed on Thursday to pay $5 million to settle charges by the Federal Trade Commission that the company had misrepresented the price of certain prescription drugs in one of its Medicare drug plans, causing many older consumers to pay significantly higher prices than advertised.

13 Jan 2012

Medicine may not be a remedy for heartburn

ABC News on December 27th, 2011 with Diane Sawyer featured "Reports of Acid Reflux Symptoms Double" and the epidemic in heartburn issues amongst the United States population, attributing the eating habits of the Baby Boomer generation as the primary cause.

13 Jan 2012

Walgreen-Express Scripts spat leads millions of consumers to new pharmacies

A Walgreen official maintained a defense of the split even as rival drug stores have ramped up their marketing efforts to attract Express Scripts customers.

13 Jan 2012